https://doi.org/10.5812/iji.86734

The Seroprevalence of Toxoplasma, Cytomegalovirus and Rubella Infections in Women with Abortion in Kurdistan Region of Iraq: A Brief Report

authors:

avatar Nawfal Hussein ORCID 1 , * , avatar Amer A Balatay 2

Department of Internal Medicine, College of Medicine, University of Duhok, Duhok, Iraq
College of Pharmacy, University of Duhok, Duhok, Iraq
International Journal of Infection: Vol.6, issue 1; e86734
published online: January 19, 2019
article type: Brief Report
received: November 24, 2018
revised: January 4, 2019
accepted: January 9, 2019

how to cite: Hussein N, Balatay A A. The Seroprevalence of Toxoplasma, Cytomegalovirus and Rubella Infections in Women with Abortion in Kurdistan Region of Iraq: A Brief Report. Int J Infect. 2019;6(1):e86734. https://doi.org/10.5812/iji.86734.

Abstract

Background:

Infection with toxoplasma, cytomegalovirus (CMV) or rubella is associated with negative pregnancy outcomes.

Objectives:

The aim of this study was to determine the prevalence of anti-toxoplasma, CMV and rubella IgM antibodies in women with abortion.

Methods:

This was a cross sectional study conducted in Kurdistan region of Iraq. Samples were collected between January 2015 and October 2018. Women with a recent history of abortion were included in the study and electrical chemiluminescence immunoassay (ECLIA) was used to determine the IgM positivity.

Results:

Overall, 1275 women were recruited. Amongst these cases, 36 out of 1275 (2.82%) were positive for anti-toxoplasma IgM antibodies. Additionally, 29 out of 1275 (2.27%) of the samples were positive for anti-CMV IgM antibodies, and 22 out of 1275 (1.73%) were positive for anti-Rubella IgM antibodies.

Conclusions:

The prevalence of toxoplasmosis, CMV, and rubella IgM positivity was low in women with abortion. It seems that infections with these microorganisms are not major causes of abortion in the studied region.

1. Background

Toxoplasmosis is a parasitic infection caused by the intracellular protozoan Toxoplasma gondii (1). According to the geographical area, the prevalence rates of toxoplasma in women of reproductive age or pregnant women ranges from 10% to 75% (1). Congenital toxoplasmosis occurs in approximately 1.5 cases per 1000 live births (2). Acute toxoplasmosis is usually subclinical with no or mild symptoms. However, acute infection acquired during pregnancy can cause negative pregnancy outcomes. Worldwide, cytomegalovirus infection is one of the most common viral infections. The seroprevalence of CMV in the adult population ranges from 50% in developed countries to 90% in some developing countries (3). In the most severe cases of congenital infection, this virus might cause abortion and stillbirth. In milder cases, CMV congenital infection can cause hearing loss, vision loss, microcephaly, and seizure (3, 4). The risk of primary CMV infection is around three percent, and 0.5% of live birth babies are born with congenital CMV infection (3, 4). Anti-CMV IgM antibody positivity indicates primary infections or reactivation of infection, both of which are associated with congenital abnormalities in pregnancy (5).

German measles is caused by rubella. Such an infection during pregnancy is associated with an overwhelming consequence on the growing fetus (6). A collection of congenital anomalies caused by rubella is known as congenital rubella syndrome. Additionally, German measles during pregnancy may lead to abortion and stillbirth (6). While a positive anti-rubella IgG indicates a previous exposure or immunization, IgM positivity indicates recent infection, which is associated with negative pregnancy outcomes (6).

2. Objectives

Several reports have documented the relationship between these infections and abortion (4, 7-9). No study has been conducted in the region investigating the prevalence of these infections in women with abortion. The aim of this paper was to investigate the prevalence of anti-toxoplasma, CMV, and Rubella IgM in women with early pregnancy loss in Kurdistan region of Iraq.

3. Methods

3.1. Study Design

This was a cross sectional study conducted in the Kurdistan region of Iraq. Samples were collected from five major cities, including Duhok, Summail, Zakho, Akre, and Amedi. Samples were collected between January 2015 and October 2018. Inclusion criteria were a history of abortion within the prior four weeks, abortion with no clear causes, and consent to participate in the study. Patients with chronic diseases, including hypertension and diabetes, were excluded.

3.2. ECLIA

In total, 5 CC of blood was taken from patients and the serum was separated by centrifuging samples for five minutes at 1500 g. Then, all samples were kept at -20° before testing. IgM antibodies against the organisms were tested using ECLIA (Cobas, Roche, Germany). All tests were conducted in duplicates.

3.3. Ethics

This project and the consent were approved by the ethics committee of the college of pharmacy, University of Duhok. Informed consent was obtained from all recruited subjects.

4. Results

4.1. Patients

During the study period, 1275 samples were collected and tested for the required IgM levels. Samples were collected from five major cities, including Duhok (575 samples), Summail (189 samples), Zakho (201 samples), Akre (150 samples), and Amedi (160 samples). The average age of women was 17 to 45 years old.

4.2. Toxoplasma, CMV and Rubella Positivity

Amongst these, 36 out of 1275 (2.82%) were positive for anti-toxoplasma IgM antibodies. Additionally, 29 of 1275 (2.27%) of the samples were tested positive for anti-CMV IgM antibodies. Finally, 22 of 1275 (1.73%) were positive for anti-Rubella IgM antibodies. Positive patients diagnosed with either toxoplasma, CMV or rubella and no co-infections (with the toxoplasma, CMV and rubella) were detected.

5. Discussion

This project was carried out to show the prevalence of acute toxoplasmosis, CMV, and Rubella infections in women with early loss of pregnancy. More than 30% of the world’s population were infected with toxoplasma (10). Such an infection is associated with negative outcomes in pregnancy. In a study conducted in Japan, the overall seroprevalence of Toxoplasma was 10% (11). In a study conducted in Turkey, women at the childbearing age were tested for anti-toxoplasma IgM and IgG, and 1.34% and 24.61% of the samples were tested positive for IgM and IgG, respectively (12). In another study conducted in Iran, T. gondii IgG and IgM antibodies were detected in 27.2% and 1.2% of women with abortion (4). In the same study in Iran, no association was found between toxoplasmosis and abortion (4). In the current study, 2.8% of women, who had abortion were tested positive for anti-toxoplasma IgM. Thus, the prevalence of acute toxoplasmosis was low in women with abortion in the region of study. More studies are needed to investigate the role of toxoplasmosis in the development of congenital abnormalities. No treatment is required for such immunocompetent patients (13, 14). The treatment for toxoplasma in immunocompetent patients is only indicated in pregnancy and three months before conception, otherwise no specific treatment is required (13, 14).

CMV IgG and IgM prevalence has been reported in the range of 23% to 100% and 2.5% to 8.0% in the childbearing age and pregnant women from different regions of Iran (4). In a study conducted in the USA, the seroprevalence of CMV IgM was 2.8% (15). Additionally, IgM seroprevalence in French women in the reproductive age was reported as 4.1% (16). In the current study, the prevalence of IgM positivity was 2.27%. Acute CMV infection is a self-limiting disease and no specific treatment is required (13, 17). Some reports showed a benefit of valacyclovir in treating congenital CMV infection. However, the role of this medication is still under investigations (18).

Additionally, a study conducted in Iran showed that more than 96% of the recruited women in Iran were positive for anti-rubella IgG (19), and 55% of women in Turkey were found to be positive (20). In another study conducted in Iran, rubella IgG and IgM seropositivity were detected in 75.3% and 1.2% in women with abortion (4). In the current study, 1.73% of the recruited patients were anti-rubella IgM positive. The low positivity may reflect the strength of the vaccination program that was started in the late 80s of the last century.

In conclusion, the prevalence of acute toxoplasmosis, CMV, and rubella is low in women with abortion. It is recommended that patients should be screened for those infections within an acceptable timeframe. There is no antiviral treatment for CMV and rubella after abortion as the infection is self-limiting. The indications of treatment in acute toxoplasmosis is when it occurs during pregnancy or before planned conception by 12 weeks.

References

  • 1.

    Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39(12):1385-94. [PubMed ID: 19433092]. https://doi.org/10.1016/j.ijpara.2009.04.003.

  • 2.

    Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: A systematic review. Bull World Health Organ. 2013;91(7):501-8. [PubMed ID: 23825877]. [PubMed Central ID: PMC3699792]. https://doi.org/10.2471/BLT.12.111732.

  • 3.

    Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86-102. [PubMed ID: 23297260]. [PubMed Central ID: PMC3553672]. https://doi.org/10.1128/CMR.00062-12.

  • 4.

    Rasti S, Ghasemi FS, Abdoli A, Piroozmand A, Mousavi SG, Fakhrie-Kashan Z. ToRCH "co-infections" are associated with increased risk of abortion in pregnant women. Congenit Anom (Kyoto). 2016;56(2):73-8. [PubMed ID: 26499091]. https://doi.org/10.1111/cga.12138.

  • 5.

    Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: Risk estimates for clinical counselling. Lancet. 1999;353(9167):1829-33. [PubMed ID: 10359407]. https://doi.org/10.1016/S0140-6736(98)08220-8.

  • 6.

    Best JM, Castillo-Solorzano C, Spika JS, Icenogle J, Glasser JW, Gay NJ, et al. Reducing the global burden of congenital rubella syndrome: Report of the World Health Organization Steering Committee on research related to measles and rubella vaccines and vaccination, June 2004. J Infect Dis. 2005;192(11):1890-7. [PubMed ID: 16267759]. https://doi.org/10.1086/497607.

  • 7.

    Ramana BV, Reddy BK, Murty DS, Vasudevanaidu KH. Seroprevalance of rubella in women with bad obstetric history. J Family Med Prim Care. 2013;2(1):44-6. [PubMed ID: 24479042]. [PubMed Central ID: PMC3894004]. https://doi.org/10.4103/2249-4863.109943.

  • 8.

    Malik A, Rizvi M, Khan F, Khan N, Rabbani T, Khan HM. Toxoplasma gondii in women with bad obstetric history and infertility: A five-year study. Asian Pac J Trop Dis. 2014;4:S236-9. https://doi.org/10.1016/s2222-1808(14)60446-1.

  • 9.

    Ghasemi FS, Rasti S, Piroozmand A, Bandehpour M, Kazemi B, Mousavi SG, et al. Toxoplasmosis-associated abortion and stillbirth in Tehran, Iran. J Matern Fetal Neonatal Med. 2016;29(2):248-51. [PubMed ID: 25564725]. https://doi.org/10.3109/14767058.2014.996127.

  • 10.

    Flegr J, Prandota J, Sovickova M, Israili ZH. Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014;9(3). e90203. [PubMed ID: 24662942]. [PubMed Central ID: PMC3963851]. https://doi.org/10.1371/journal.pone.0090203.

  • 11.

    Sakikawa M, Noda S, Hanaoka M, Nakayama H, Hojo S, Kakinoki S, et al. Anti-Toxoplasma antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clin Vaccine Immunol. 2012;19(3):365-7. [PubMed ID: 22205659]. [PubMed Central ID: PMC3294603]. https://doi.org/10.1128/CVI.05486-11.

  • 12.

    Akyar I. Seroprevalence and coinfections of Toxoplasma gondii in childbearing age women in turkey. Iran J Public Health. 2011;40(1):63-7. [PubMed ID: 23113056]. [PubMed Central ID: PMC3481714].

  • 13.

    Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's principles of internal medicine. New York, NY: McGraw-Hill; 2015.

  • 14.

    Wei HX, Wei SS, Lindsay DS, Peng HJ. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS One. 2015;10(9). e0138204. [PubMed ID: 26394212]. [PubMed Central ID: PMC4578932]. https://doi.org/10.1371/journal.pone.0138204.

  • 15.

    Wang C, Dollard SC, Amin MM, Bialek SR. Cytomegalovirus IgM seroprevalence among women of reproductive age in the United States. PLoS One. 2016;11(3). e0151996. [PubMed ID: 26990759]. [PubMed Central ID: PMC4798411]. https://doi.org/10.1371/journal.pone.0151996.

  • 16.

    Leruez-Ville M, Sellier Y, Salomon LJ, Stirnemann JJ, Jacquemard F, Ville Y. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: A retrospective cohort. Clin Infect Dis. 2013;56(10):1428-35. [PubMed ID: 23392397]. https://doi.org/10.1093/cid/cit059.

  • 17.

    Tan BH. Cytomegalovirus treatment. Curr Treat Options Infect Dis. 2014;6(3):256-70. [PubMed ID: 25999800]. [PubMed Central ID: PMC4431713]. https://doi.org/10.1007/s40506-014-0021-5.

  • 18.

    Pass RF, Arav-Boger R. Maternal and fetal cytomegalovirus infection: Diagnosis, management, and prevention. F1000Res. 2018;7:255. [PubMed ID: 29560263]. [PubMed Central ID: PMC5832908]. https://doi.org/10.12688/f1000research.12517.1.

  • 19.

    Honarvar B, Moghadami M, Moattari A, Emami A, Odoomi N, Bagheri Lankarani K. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: Outcomes of a nationwide measles-rubella mass vaccination campaign. PLoS One. 2013;8(1). e55043. [PubMed ID: 23383049]. [PubMed Central ID: PMC3561451]. https://doi.org/10.1371/journal.pone.0055043.

  • 20.

    Sasmaz T, Kurt AO, Ozturk C, Bugdayci R, Oner S. Rubella seroprevalence in women in the reproductive period, Mersin, Turkey. Vaccine. 2007;25(5):912-7. [PubMed ID: 17049680]. https://doi.org/10.1016/j.vaccine.2006.09.033.